A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta(®) in healthy male subjects

Purpose: This is the first study to compare the pharmacokinetics, safety and, immunogenicity of QL1209, a biosimilar of Perjeta(®). Methods: This study was a randomized, double-blind, parallel-controlled clinical trial evaluating the biosimilarity between QL1209 (specification: 420 mg:14 ml, single...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yuanyuan, Yang, Heng, Yang, Xiaoyan, Yang, Shuang, Guo, Can, Chen, Honghui, Cui, Chang, Xiang, Yuxia, Yang, Guoping, Huang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445216/
https://www.ncbi.nlm.nih.gov/pubmed/36081953
http://dx.doi.org/10.3389/fphar.2022.953641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445216/
https://www.ncbi.nlm.nih.gov/pubmed/36081953
http://dx.doi.org/10.3389/fphar.2022.953641

Ejemplares similares